Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: An update

13Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

The management of patients scheduled for surgery with a coronary stent, and receiving 1 or more antiplatelet drugs, has many controversies. The premature discontinuation of antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, and cardiac death, and surgery under an altered platelet function could also lead to an increased risk of bleeding in the perioperative period. Because of the conflict in the recommendations, this article reviews the current antiplatelet protocols after positioning a coronary stent, the evidence of increased risk of ST associated with the withdrawal of antiplatelet drugs and increased Bleeding risk associated with its maintenance, the different perioperative antiplatelet protocols when patients are scheduled for surgery or need an urgent operation, and the therapeutic options if excessive bleeding occurs. © 2010 Llau et al, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Llau, J. V., Ferrandis, R., Sierra, P., & Gómez-Luque, A. (2010). Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: An update. Vascular Health and Risk Management. https://doi.org/10.2147/VHRM.S7402

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free